Trial Profile
A Randomised, Placebo-controlled, Double-blind, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Escalating Subcutaneous Doses of Glutazumab in Subjects with Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Sep 2020
Price :
$35
*
At a glance
- Drugs Glutazumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 31 Aug 2020 Status changed from recruiting to completed.
- 13 Jul 2018 New trial record
- 22 Jun 2018 According to a Gmax Biopharm media release, this study will be presented at the 78th American Diabetes Association Scientific Sessions.